New-onset breast discomfort has been linked to an increase in breast tissue density on mammography in postmenopausal women taking combination hormone therapy, which in turn is associated with an increased threat of breast cancer, according to the findings of a recent UCLA study.
New-onset breast discomfort has been linked to an increase in breast tissue density on mammography in postmenopausal women taking combination hormone therapy, which in turn is associated with an increased threat of breast cancer, according to the findings of a recent UCLA study.
Carolyn J. Crandall, MD, MS, and colleagues used data from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study, which involved mammograms for almost 600 women between the ages of 45 and 64 years.
Compared with women without new-onset breast discomfort, the researchers found that women taking estrogen/progestin combination therapy with new-onset discomfort had a significant increase in percent breast density at 12 months (0.6% vs. 3.9%; β=0.033, P<0.001).
Crandall CJ, Karlamangla A, Huang MH, et al. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. Arch Intern Med. 2006;166:1578-1584.
Commentary by Victoria Green, MD, MBA, JD, Associate Professor, Department of Gynecology and Obstetrics, Emory University, Atlanta, Ga.:
Although the study involved a short surveillance period, this appears to be the first data gathered in a placebo-controlled, randomized, blinded design to review self-reported breast discomfort where increased mammographic breast density was also linked to late age at first delivery and increased postmenopausal BMI. Ultimately, further research must determine whether increased mammographic density in the context of hormone therapy definitely heralds an increased risk of breast cancer.
Disparities in kidney care access for pregnant patients
December 11th 2023A recent study highlights significant disparities in kidney transplant and nephrology care access for pregnant patients with end-stage kidney disease, revealing reduced survival rates and limited access to crucial care compared to non-pregnancy-related causes.
Read More
Mediterranean diet linked to improved pregnancy outcomes
December 8th 2023A comprehensive meta-analysis scrutinizes the Mediterranean diet's impact on female reproductive health, uncovering compelling evidence that links this nutritional approach to a significant reduction in adverse pregnancy outcomes.
Read More
FDA grants IND clearance to DARE-VVA1 for dyspareunia
December 7th 2023Daré Bioscience's tamoxifen-based therapy, DARE-VVA1, secures FDA clearance for an investigational new drug application, offering hope for women with contraindications to estrogen therapies suffering from the underdiagnosed condition of vulvar and vaginal atrophy.
Read More